Definium says LSD therapy DT120 helped major depression in first Phase 3 trial
STAT+: Definium LSD therapy helped patients with major depression in late-stage trial
Definium Therapeutics said on Monday that its LSD therapy DT120 significantly helped patients with major depression in its first Phase 3 trial. Six weeks after a single dose。
The topline gives the first Phase 3 readout for an LSD-based depression treatment, so the size of the placebo gap and the waning at 12 weeks are the numbers that will shape the next regulatory step.
Key facts
- Kind of item
- Trial results
- Compound
- LSD
- Condition
- Depression
- Trial phase
- Phase 3
- Source
- STAT: psychedelics (statnews.com)
- Published
- Original
- Read it at statnews.com
How this summary was made
The summary and the “Why it matters” note were written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: STAT: psychedelics · statnews.com
Connected to
- Kind of item
- Trial results
- Compound
- LSD
- Condition
- Depression